Abstract
Introduction

7
Genomic instability in cancers is a continuous process involving genetic alterations at gene or 8 chromosomal level. Extreme genetic heterogeneity drives a tumor from its benign state to 9 malignancies. Tumor multi-region sequencing revealed intra-tumor heterogeneity and clonal 10 evolution which play a key role in progression and metastases of the tumor, as well as 11 identifying and developing novel targets for target-based precision medicine in personalized 12 cancer therapy 1 . The development of effective target-based precision medicine and 13 personalized cancer therapy is based on intra-tumor heterogeneity and the pattern of clonal as 14 well as subclonal evolution in CRC tumors 2 . Therefore, patients with CRC may respond 15 variably to the same treatment, due to intra-tumor heterogeneity, despite there being no 16 significant differences identified in the tumor histopathology 3 . In addition, mono-sampling 17 biopsies for clinical diagnosis are inadequate, due to intra-tumor heterogeneity 4 . Hence, study 18 of intratumor heterogeneity is highly significant from both clinical and biological perspective, 19 to understand the genomic changes driving the malignant process, which is fundamental to 20 developing an effective personalized cancer therapy. 21 CRC is the third most common malignancy and the second leading cause of cancer death 22 worldwide, with 18.1 million new cancer cases, and 9.6 million deaths in 2018 5 . According to 23 samples, and calculate the variant alleles and allelic frequencies from tumor samples. The 1 sequenza-utils output was further processed by using Sequenza R package to provide 2 segmented copy number data, cellularity and estimated ploidy for each sample. All segmented 3 copy number data has given in Supplementary Table S3 in the Supplementary Appendix. 4 Heatmap of genome-wide SCNAs is visualized by R package Copynumber (v1.24.0) 43 . 5 The driver gene copy number variations (driver SCNAs) of all genes enlisted in the 6 COSMIC cancer gene census were analyzed as follows. Firstly, if the gene is annotated as 7 oncogene by COSMIC, gene level amplification was called if gene copy number >2x ploidy of 8 that sample. Secondly, if the gene was annotated as TSG by COSMIC, gene level deletion was 9 called if gene copy number = 0. To determine the intratumor heterogeneity (ITH) status of 10 driver SCNAs, we called driver SCNAs across all regions from each tumor. If at least one region 11 showed an amplified SCNA, we called a gene as clonal amplification if all other regions of this 12 gene showed copy number > ploidy + 1. If at least one region showed a deleted SCNA, we 13 called a gene as clonal deletion if all other regions of this gene showed copy number < ploidy 14 -1. All other driver SCNAs were defined as subclonal amplification or deletion. In 8 polyclonal 15 origin tumors (CRC32, CRC36, CRC42, CRC48, CRC49, CRC51, CRC52 and CRC60) 16 without founder clusters (cluster with CCF > 0.9 across all regions of a tumor), all their driver 17 SCNAs were subclonal. To correlate driver SCNAs with specific mutation clusters of PyClone, 18 we first identified all clusters where >= 50% CCF was present in each tumor region. We then 19 identified all the clusters present in the same regions as a given driver SCNAs. If more than one 20 clusters were found, then chose the one which is closer to the trunk. If no clusters matched for 21 a given SCNA, we re-called the clonality of the SCNA by using the following threshold. We 22 called a gene as clonally amplified if all the regions of this gene showed copy number >2x 23 ploidy while we called a gene as clonally deleted if all the regions of this gene showed copy 24 number = 0. Then we repeated the association test above. If an SCNA still could not be 25 associated with a mutant cluster, it was annotated as a subclone associated with no known 26 cluster (NA cluster). 27 To determine the ITH status of global SCNA, all parts of the genome were considered 28 independently and divided into the smallest contiguous segments that overlap in all the regionswithin each tumor. The gains and losses of segment were determined as follows. Firstly, copy 1 number data for each segment was divided by the sample mean ploidy and then converted to 2 log2. Secondly, gain and loss were defined as log2 (2.5/2) and log2 (1.5/2), respectively. Thirdly, 3 any segment of gain or loss that spanned across all the regions was defined as clonal and all 4 other segments of SCNA were defined as subclonal. Within each tumor, we summarized the 5 length of the genome that subjected to SCNA in any region (total SCNA), the length of the 6 genome that subjected to clonal SCNA (clonal gain or clonal loss), and the length of the genome 7 that subjected to subclonal SCNA (subclonal gain, subclonal loss or subclonal undetermined). 8 The proportion of subclonal SCNAs were then defined as the percentage of genomes subjected 9 to subclonal SCNA divided by the percentage of genomes subjected to total SCNAs. 10 Chromosomal arm level SCNAs were determined if at least one region has shown an 11 increase or decrease of at least 97% in chromosomal arm. To determine the ITH status of 12 chromosome arm gain and loss, we called clonal arm gain or loss if the same chromosomal arm 13 showed at least 75% gain or loss in all the remaining regions. While we called subclonal arm 14 gain or loss if at least one of the remaining regions showed less than 75% gain or loss. For 8 15 polyclonal origin tumors (CRC32, CRC36, CRC42, CRC48, CRC49, CRC51, CRC52 and 16 CRC60) without founder clusters (cluster with CCF > 0.9 across all regions of a tumor), all 17 their arm level SCNAs were subclonal. As previously described in the driver SCNAs part, we 18 correlated arm level SCNAs with specific mutation clusters of PyClone in the same way. 19
Mirrored sub-clonal allelic imbalance analysis 20
Single nucleotide polymorphisms (SNPs) were called by using Platypus (v0.8.1) 44 and only 21
SNPs with a minimum coverage of 20x were analyzed. The B allele frequency (BAF) of each 22 SNP was calculated as the ratio of reads of reference base to variant. Heterozygous SNPs and 23
BAFs were used as input and mirror subclone allelic imbalances (MSAI) were analyzed and 24 visualized by RECUR 45 . 25 Parallel evolution events for driver SCNAs were identified as follows. Firstly, driver 26 SCNAs were identified as described in the "copy number analysis" section. Secondly, we 27 annotated the regions of MSAI events in each tumor to the events of driver SCNAs. If twoevents coincided with each other, then these driver SCNAs undergone parallel evolution. 1
Sub-clonal deconstruction 2
In order to estimate whether mutations were clonal or subclonal, and the phylogenetic trees of 3 each tumor, the following formula were used 22, 46 : 4
Where vaf is the mutated allele frequency of the mutated base; p is the estimated tumor purity; 6 CNt is tumor locus specific copy number; CNn is normal locus specific copy number, assuming 7 2 for autosomal chromosomes; CCF is the fraction of tumor cells = carrying mutations. 8
Considering that CNmut is the copy number of the chromosome harboring the mutation, the 9 possible CNmut range is from 1 to CNt (integer). We then assigned one of the possible values 10 to CCF: 0.01, 0.02, ..., 1, together with every possible CNmut to find the best fit CCF using 11 maximum likelihood. In detail, for point mutations with alternative reads as "a" and sequencing 12 coverage as "N", we used Bayesian probability theory and binomial distribution to estimate the 13 probability of a given CCF: 14
Then, the distribution of CCF was obtained by calculating P (CCF) on 100 uniform grids with 16 CCF values from 0.01 to 1 and dividing by their sum. 17 Then, we used PyClone (v.0.12.9) 41 Dirichlet process clustering to cluster all the mutations 18 (SNVs and INDELs). For each mutation, we used the observed mutation count and set the 19 reference count so that vaf equal to half of the CCF value calculated by maximum likelihood 20 previously. We set the major allele copy number to 2, the minor allele copy number to 0 and 21 the purity to 0.5 since they had been modified. 22 Since the vaf values of INDELs were potentially unreliable, we multiplied each estimated 23 INDEL CCF with a region-specific correction factor, which was calculated by dividing the 24 median mutation CCF of the ubiquitous mutations (mutations presented in all regions) in that 25 region by the median INDEL CCF of the ubiquitous INDELs (INDELs presented in all regions) 26 in that region. We ran PyClone with 10,000 iterations and a burn-in of 1000.
Phylogenetic tree construction 1
Phylogenetic trees were constructed using the published tool CITUP (v0.1.0) 47 . As input, 2 CITUP requires mutation clusters and their mean cancer cell prevalence values which were 3 collected from PyClone. All clusters with at least 5 mutations were used as input to CITUP. 4 Clusters for phylogenetic tree construction were summarized in Supplementary Table S4 in 5 the Supplementary Appendix. The optimal phylogenetic trees for each patient from CITUP 6 were illustrated using MapScape (v.1.8.0) 48 . 7
Evolution subtype analysis 8
Evolutionary subtypes were clustered and visualized by REVOLVER (v.0.2.0) 49 . CCF values 9
and cluster information of driver mutations, driver SCNAs and arm level SCNAs were 10 processed as previously described, which were used as input to REVOLVER. REVOLVER 11 requires a founder cluster for all the input tumors. Therefore, we artificially defined a founder 12 cluster for 8 polyclonal origin tumors. For CRC32, CRC36, CRC42, CRC48, CRC49, CRC51, 13 CRC52 and CRC60, the artificial founder cluster was cluster 2, cluster 2, cluster 1, cluster 2, 14 cluster 3, cluster 1, cluster 2 and cluster 5, respectively. 15
Phylogenetic analysis 16
Phylogenetic distance between primary tumor, LN and ENTD were analyzed by using the 17 binary matrix of mutations present or absent in each region of tumors with LN or ENTD. Private 18 mutations of each region were discarded from phylogenetic tree building due to lack of 19 information. Fake outgroups with no mutations were generated for each individual as a root. 20 Phylogenies were constructed using the PHYLIP (v. 
Statistical analysis 10
All analyses were performed in R statistical environment version >= 3.5.0. All statistical 11 comparisons of two distributions used the Wilcoxon test (wilcox.test function in R). 12
Data availability 13
The sequencing data and supplementary tables has been deposited at the CNGB Nucleotide 14 Sequence Archive (CNSA: https://db.cngb.org/cnsa), under accession number CNP0000594. 15
Results
16
Comprehensive clinical description of these 68 patients are provided in Supplementary ) (Supplementary Figure S3) . In our study, the mutation rate of single 6 sample sequencing was significantly higher than single CRC sample sequencing data from The 7
Cancer Genome Atlas 54 (TCGA), probably due to the higher sequencing depth in our study 8 Figure S5) . 21 Somatic copy number alterations (SCNAs) were measured as length of segments affected 22 by either gains or losses (detailed copy number data has given in Supplementary Table S3) . 23 We summarized the total length of the genome that subjected to SCNAs and calculated the 24 percentage of clonal and subclonal SCNAs ( Figure 1A) . Interestingly, in a patient (CRC43) 25 with a rectal tumor, all SCNAs were subjected to subclonal SCNAs. There were no significant In our study, we identified that the mutation frequency of 14 driver genes (APC, TP53, 1
KRAS, LZTR1, LRP1B, FBXW7, TCF7L2, FAT4, ARID1A, ATM, PIK3CA, AMER1, CSMD3 2
and SMAD4) were higher at patient-level than at sample-level, except SMAD4 gene (Figure  3 1B). In addition, we also found that the mutation frequency was higher at patient-level 4 compared to the TCGA study 54 except CSMD3 gene ( Figure 1B) . Notably, the mutation 5 frequency of the LZTR1 gene was also much higher than TCGA study 54 ( Figure 1B ). We also 6 identified that the frequency of SCNAs was higher than TCGA 54 study data, probably due to 7 the identification of subclonal SCNAs in our study ( Figure 1C) . was not enough to capture all the genetic information within a tumor. 26
Driver event alterations in CRC evolution
Identifying cancer driver events and their clonality might provide important evidences for 1 developing the target-based effective therapeutic strategies. Therefore, driver mutations, driver 2 SCNAs, arm level SCNAs and their clonality were analyzed for CRC tumors (Figure 3) . 3 We identified 1373 driver events (405 driver mutations, 707 driver SCNAs and 261 arm 4 level SCNAs) among 62 CRC tumors. Of these events, 55% of driver events (611 out of 1373) 5 were found to be subclonal (41% of driver mutations, 41% of driver SCNAs and 60% of arm 6 level SCNAs). However, significantly lower percentage of clonal driver events and more 7 subclonal driver mutations were identified in rectal tumors than patients with both right-sided In addition, no driver events were consistently clonal among 62 CRC tumors, suggesting 16 high ITH status and evolutionary diversity among CRC tumors, which might be the reason of 17 low efficiency of target-based precision medicine in CRC treatment (Figure 3) . All the driver 18
SCNAs and most of the driver mutations were early events while very few arm level SCNAs 19 were early events, suggesting that genomic instability process occurred firstly at the driver 20 SCNA level, then at the driver mutations level, and finally at the driver arm level SCNA level. were the same in patients with left-sided and rectal tumors while only 3 out of 24 genes of 28 driver SCNAs (CYSLTR2, FLT3 and FOXO1) were same in patients with right-sided and leftsided colon tumors (Figure 3) . The huge differences in both driver mutations and driver SCNAs 1 between the patients with right-sided and left-sided colon tumors suggested that left-sided colon 2 tumors were evolutionary closer to rectal tumors than to right-sided colon tumors. 3 Chromosomal arm level gain of 13q and loss of 18q were mostly occurred and predominantly 4 clonal and early in colon and rectal cancer patients except that gain of 13q were late events in 5 rectal cancer. 6 
Convergent features and parallel evolution in CRC 7
Evidence of convergent mutations in tumor driver genes may shed light on evolutionary 8 selection, which may provide therapeutic targets for treatment. APC, TP53 and KRAS were the 9 most frequently mutated driver genes identified in our study, 80.6 % (50 / 62), 80.6 % (50 / 62) 10 and 51.6 % (32 / 62) respectively (Supplementary Figure S14 and S15). Among these three 11 genes, APC was the most often mutated gene in CRC patients. Among the 50 CRC tumors with 12 APC mutations, 19 (38%) had 2 mutations, consistent with the two-hit hypothesis of APC genes 13 in CRC tumorigenesis (Supplementary Figure 15) . 14 Evolutionary selection was also exemplified by parallel evolution of driver mutations, in 15 which different driver mutations in distinct regions of the same tumor converge on the same 16 gene. In CRC36 (left-sided colon tumor), two mutations (one splicing and one nonsynonymous 17 mutations) in TP53 were detected in tumor region 1 and 4 while another nonsynonymous 18 mutation of TP53 was detected in tumor region 3, indicating parallel evolution of TP53. 19 
Positive selection 20
In order to further evaluate evolutionary selection at the mutational level, we used the ratio of 21 dN/dS, which could reflect the degree of enrichment of protein-altering mutations occurred. 22 As shown in Supplementary Table S5, evidence for positive selection (dN/dS>1 based 23 on the 95% confidence intervals) was rejected when all the non-synonymous mutations were 24 considered. However, when genes were narrowed to all driver genes identified in the COSMIC 25
Cancer Gene Census (v88), positive selection was observed for all clonal non-synonymous 26 mutations in rectal tumors, but not in colon tumors. These findings suggested that positiveselection happened in cancer driver genes in early stage of CRC evolution. 1
Mutation signature 2
We analyzed mutational processes for CRC evolution by using published mutational 3 signatures 55 . We found that the age-related signature 1 was the predominant mutational process 4 for CRC tumors, with a median percentage of age-related mutations of 70% (Supplementary 5 Figure S16 ). Interestingly, in a patient (CRC66) was identified with all the mutations with age-6 related signature 1 while in another patient (CRC63) was identified with defective DNA 7 mismatch repair-related signature 6 and 15. 8
The median percentage of age-related signature 1 in CRC tumors for clonal mutations was 9 73%, while it dropped to 53% for subclonal mutations (Supplementary Figure S16) . This 10 finding suggested that except for age, other mutational processes played more important roles 11 in subclonal than clonal tumors, which accounted for ITH of CRC. Except for age, other main 12 mutation processes were defective DNA mismatch repair-related signature 6, defective DNA 13 double-strand break-repair-related signature 3 and defective DNA mismatch repair-related 14 signature 15, suggesting that the main mutational process for ITH of CRC were age and 15 defective of DNA repair system. 16
Chromosome instability 17
Previously we analyzed the length and clonality of SCNAs relatively to ploidy ( Figure 1A) , we 18 then measured the absolute SCNAs in CRC tumors. SCNAs and ITH of SCNAs were 19 ubiquitous, which described the continuing process of chromosome instability in CRC tumors 20 Figure S17 and S18) . Left-sided colon tumor were found to have more loss 21 type of SCNAs (total copy number = 0 or 1, or copy neutral loss of heterozygous) than rectal 22 cancer (P=0.007) and have more SCNAs with total copy number equal to 1 than right-sided 23 colon tumors (P=0.044) (Supplementary Figure S17) . Late stage tumors were identified with 24 significantly fewer SCNAs than early stage CRC tumors (P=0.016) (Supplementary Figure  25   S18 ). Specifically, the late stage CRC tumors had significantly fewer SCNAs with total copy 26 number equal to 4 than early stage CRC tumors (P=0.043) (Supplementary Figure S18) .Interestingly, we found that the late stage CRC tumors had significantly more subclonal driver 1 SCNAs than early stage CRC tumors, which suggested that the loss of random SCNAs as well 2 as enrichment of functional SCNAs in late stage CRC tumors (Supplementary Figure S12) . 3 The SCNA frequency pattern in patients with left-sided colon tumors and rectal tumors 4 were similar to each other, while right-sided colon tumors were very different (Supplementary 5 Figure S19 ). Patients with right-sided colon tumors had more 9p gain, 3q gain, 19p loss and 6 less 20q gain, 19p loss, 8p loss than all CRC tumors (Supplementary Figure S19) . (Supplementary Figure S20) . Interestingly, both poor prognosis location 9 (right-sided colon tumors) and stage (late stage of CRC tumors) of CRC tumors had more 9p 10 
(Supplementary
Late stage 7 CRC tumors had more 13q gain, 9p gain, 21p gain, 11q loss, 21q loss and 12p loss than early 8 stage CRC tumors
gain. 11
Genome doubling 12
If the percentage of autosomal tumor genomes with a major copy number of two or more in a 13 tumor were 50% or more than 50%, then this tumor was classified as genome doubling tumor 56 . 14 Genome doubling events were identified in 76% of tumors (found in 47 out of 62 tumors, 9 15 right-sided colon tumors, 15 left-sided colon tumors, and 23 rectal tumors) and appeared to be 16 clonal in 66% of tumors (found in 31 out of 47 tumors, 5 right-sided colon tumors, 11 left-sided 17 colon tumors and 15 rectal tumors), which suggested that whole genome doubling was an early 18 event in CRC evolution. In our study, we identified that the rate of whole genome doubling was 19 much higher than 36% found in a previous study of CRC 56 , and the high rate was likely to come 20 from multi-region sequencing because 16 out of 47 CRC were identified with subclonal whole 21 genome doubling. 22 We observed a strong positive correlation between genome doubling with the ITH of both 23 mutations and SCNAs. (Supplementary Figure S21 and S22) Figure S22) . 3
Mirrored subclonal allelic imbalance 4
Recent studies identified parallel evolution of SCNA in NSCLC and renal cancer through 5 mirrored subclonal allelic imbalance (MSAI) 22, 24 , which was defined as the maternal allele was 6 gained or lost in a subclone in one region, yet the paternal allele was gained or lost in a different 7 subclone in another region. We identified 53 MSAI events in 23 of 62 CRC tumors (37%, found 8 in 5 right-sided colon tumors, 6 left-sided colon tumors and 12 rectal tumors) (Supplementary 9 Figure S23 ). MSAI parallel gain or loss events found in this study were summarized ( Figure  10 4A). Chromosomal regions of 7p and 13q were identified with parallel gain events in 3 tumors 11 and chromosomal regions of 21q were identified with parallel loss events in 4 tumors. We also 12 analyzed parallel evolution of driver SCNAs, 5 tumors (4 tumors of parallel amplification and 13 1 tumor of parallel deletion) were found to have driver SCNAs which overlapped with MSAI 14 events ( Figure 4B and C) . Interestingly, 2 of 5 patients (CRC12 and CRC59) were identified 15 with parallel amplification of FLT3 gene in chromosome 13 ( Figure 4C) . 16 
Conserved evolutionary features in CRC 17
In order to understand the constraints and features of CRC evolution, we analyzed conserved 18 patterns of driver events by REVOLVER 49 and patient age (Figure 5) . 26 We found that the red and blue clusters had relatively fewer driver events than green andpurple clusters. There were no specific genomic or clinical features for the tumors in red cluster. 1 The purple cluster had the most driver events compared with the other three clusters. The blue, 2 green and purple clusters had similar clinical and genomic features, which were enriched in 3 left-sided CRC tumors and tumors with genome doubling type. 4
Phylogenetic distance between LN and ENTD 5
We analyzed 16 non-hypermutated stage III patients to understand the phylogenetic distance 6 and evolutionary relationship amongst primary tumor, LN and ENTD. CRC21, CRC28, CRC43 7 and CRC48 were identified with both LN and ENTD samples which were sequenced (Figure  8   6 ). In CRC21, we identified that the clonal evolution of LN and ENTD was similar, while 9 ENTD appeared evolutionarily later than LN (Supplementary Figure S8) . In CRC28, two 10 ENTD were clustered together while LN were far away from them, which indicated that the 11 LN and ENTD were polyclonal in origin (Figure 6 and S8) . In CRC 43 and CRC48, we 12 identified that the ENTD were not clustered together with LN and evolved separately ( Figure  13 6 and S8). In tumors with more than one LN sequenced (CRC01, CRC11, CRC29 and CRC33), 14 some LN were clustered together while some LN were not (Figure 6 ). In tumors with two 15 ENTD sequenced (CRC60), the two ENTD were far away from each other in the phylogenetic 16 tree (Figure 6 ). These findings suggested that the LN and ENTD were polyclonal in origin. 17 LN were identified with significantly less TMB than primary tumors (P=0.035) 18 Figure S24) . LN were also presented with significantly more loss type of 19 Figure S25) which suggested that the 20 LN were distinguished from primary tumors and ENTD in absolute SCNA level. Regarding 21 SCNA frequency, the biggest difference of gain events existed between LN and ENTD while 22 the biggest difference of loss events existed between primary tumors and ENTD 23 (Supplementary Figure S26) . ENTD were identified with less 20p gain, 20q gain and 21p gain 24 than LN while ENTD had more 20p loss, 19q loss and 19p loss than primary tumors 25 (Supplementary Figure S26) , which suggested that the ENTD were different from LN and 26 primary tumor in SCNA frequency level. In conclusion, LN and ENTD were also different in 27 both mutation and SCNA level.
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SCNAs (P=0.043) than primary tumors (Supplementary
Evolution landscape of hypermutated CRC tumors. 1
All 6 (CRC04, CRC05, CRC09, CRC13, CRC15 and CRC17) hypermutated CRC patients were 2 identified with right-sided colon tumors, of these two (CRC09 and CRC13) were with MSS 3 and remaining four (CRC04, CRC05, CRC15, CRC17) were with MSI tumors 4 (Supplementary Figure S27A) . All of the 6 hypermutated tumors had mutations in mismatch-5 repair genes, POLE or POLD gene family (Supplementary Figure S27A) . CRC09 had one 6 missense mutation and one nonsense mutation of POLE. CRC13 had one missense mutation of 7 POLE (Supplementary Figure S27A) . These findings were consistent with that the 8 predominant mutational process in CRC09 and CRC13 was POLE-related signature 10 9 (Supplementary Figure S27B) . Defective DNA mismatch repair-related signature 6, 15, or 26 10 contributed to the mutational process of 4 MSI tumors (CRC04, CRC05, CRC15, CRC17) 11 Figure S27B) . 12 We next analyzed evolution landscape of hypermutated tumors in SCNA level. None of the 13 tumor regions in 6 hypermutated tumors had genome doubling. Absolute SCNAs of 14 hypermutated CRC tumors were less compared with non-hypermutated CRC tumors 15 Figure S27C and S17) , which suggested that hypermutated tumors were 16 mainly mutation driven tumors. Interestingly, CRC04 had MSAI events in X-chromosome 17 (Supplementary Figure S28) . 18 
(Supplementary
Discussion
19
In this present study, we recruited 68 patients with CRC and collected 206 multi-region tumor 20 samples including 176 primary tumor tissue samples, 19 tissue samples with LN and 11 tissue 21 samples with ENTD. We performed high-depth whole exome sequencing and analyzed 206 22 multi-region tumor samples. Our result showed very clear evidence of ITH amongst these 206 23 multi-region tumor samples in respect of both mutations and somatic copy number alterations. 24 Our result showed the specific temporal and spatial features of evolution of CRC, following a 25
Darwinian pattern of evolution. In addition, left-sided CRC was structurally and functionally 26 more complex and divergent in terms of evolutionary perspective. We also identified that both 27
ENTDs and LNs were polyclonal in origin and ENTDs were a distinctive entity from LNs,which appeared later in tumor evolution. In conclusion, our study identified a Darwinian pattern 1 of evolution of CRC and provides a potential new perspective to distinguish both left-sided 2 with right-sided CRC. 3
Evolution pattern: Darwinian pattern of evolution and neutral evolution 4 In this present study, we found predominantly Darwinian pattern of evolution (59 out of 62 5 tumors) and a small portion of linear evolution (3 out of 62 tumors). Previous studies proposed 6 neutral evolution model for colorectal cancers 14, 57, 58 , whilst our conclusion was different from 7 them, based on two reasons. Firstly, clonal events of both mutations (SNVs and INDELs) and 8
SCNAs were widespread, with a median percentage of 47% and 43% respectively. Secondly, 9 our study demonstrated a clear selection for functional mutations rather than non-functional 10 mutations in colorectal cancer. In addition, 59% of driver mutations were clonal while only 41% 11 of non-driver mutations were clonal, which indicated the enrichment of clonal driver mutations 12 in course of evolution. Furthermore, the dN/dS value was 1.03 (95% confidence interval, 0.983 13 to 1.07) for all non-synonymous mutations while it reached to 1.37 (95% confidence interval, 14
1.16 to 1.61) when we consider only cancer driver genes based on COSMIC database. These 15 findings indicated that positive selection existed only for cancer related gene mutations. Thirdly, 16 convergent and parallel events were also present for driver genes in both mutational and SCNA 17 level, especially for genes APC, TP53 and KRAS. Some studies showed that the evolution 18 pattern for colorectal cancer was Darwinian evolution followed by neutral evolution 21, 59 . In our 19 study, according to the existence of mutations in different tumor regions, 28% of subclonal 20 mutations were shared by tumor regions (branch or trunk mutations), which suggested the 21 importance of branches in phylogenetic trees. 22
Right-sided colon, left-sided colon and rectal cancer: In the light of genomic evolution 23
Previous studies 11, 60 had shown remarkable differences between right-sided (right-sided colon 24 tumors) and left-sided colon cancer (left-sided colon tumors) and rectal cancer, based on 25 histology, MSI status, genetic subtype and prognosis. Almost no research has been done to date 26 for understanding the differences between right-sided and left-sided colon cancer from an 27 evolutionary perspective. Our study demonstrated that ITH and evolution in different locationof CRC were different in the following aspects: mutation, SCNA, structure of polygenetic tree 1 and driver events. Firstly, rectal cancers had shown fewer clonal mutations than right-sided 2 colon cancers, indicating higher ITH in rectal cancer at mutational level. Secondly, the pattern 3 and clonality of SCNA frequency in right-sided colon cancer were different from left-sided 4 colon cancer, which addressed the evolutionary difference between them at SCNA level. 5 Thirdly, the structure of phylogenetic trees in left-sided colon cancer were more complicated 6 and branched than that of the right-sided colon cancer. Specifically, left-sided colon cancer had 7 the most complicated structure of the phylogenetic tree, reflected by the more cluster numbers. 8
In addition, only left-sided colon cancer had polyclonal origin. Fourthly, left-sided colon cancer 9 was enriched in clusters (blue and purple clusters) which had more driver events. These findings 10 indicated that left-sided colon cancer had more functional diversity in the course of evolution. 11
Specifically, rectal cancer had less percentage of clonal driver events than colon cancer, 12 indicating more functional diversity occurred in the process of evolution in rectal cancer. In 13 conclusion, our data showed that left-sided colon cancer were more divergent and complicated 14 in terms of evolution than right-sided colon cancer, not only structurally but also functionally, 15 which indicated that the evolutionary diversity might play an important role in the initiation 16 and progression of left-sided colon cancer. Moreover, the frequency and clonality of SCNA was 17 a potential and significant biomarker to distinguish right-sided colon cancer from the left-sided 18 colon cancer. 19
Primary tumor, LN and ENTD: In evolutionary perspective 20
To date, no systematic research studies have been done to understand the similarities and 21 differences between ENTD and LN. In this study, we found that ENTD were later events in the 22 evolution of the tumor than LN, which could be distinguished at mutational, SCNA and 23 evolutionary levels. At the mutational level, the TMB of LN was significantly less than primary 24 tumors. Also, LN and ENTD could not be clustered together in the polygenetic tree according 25 to the occurrence of mutations. Unlike in previous studies 15, 61, 62 , different LNs or ENTDs in the 26 same tumor did not cluster together in all cases, indicating the polyclonal origin of both LN and 27 ENTD. We also identified here that LN were different from ENTD at SCNA level. In addition, 28 LN had significantly more SCNA loss than the primary tumor. However, the biggest difference 29 between LN and ENTD was gain of events in SCNA frequency. ENTD thus appeared to be as 1 later event than LN according to the clonal evolution history in CRC21. In conclusion, our 2 present study provided comprehensive evidences to prove that ENTD and LN were two 3 distinctive entities. These findings suggest the 7th and 8th editions of TMN staging, should 4 separate ENTD as a distinctive entity from LN. 5
Stage and ITH in CRC 6
There was no significant difference between early and late stage of CRC at both mutational and 7 evolution (cluster number) level. It was well known that chromosomal instability was 8 associated with a worse prognosis. Therefore, we analyzed the difference between early and 9 late stage of CRC at SCNA level. There was no significant difference in length and clonality of 10 SCNA relatively to ploidy between early and late stage of CRC in our study. However, early 11 stage CRC were found to have significantly more absolute SCNAs than late stage CRC in our 12 study. These two distinctive conclusions suggested the definition of chromosomal instability 13 was important. Interestingly, late stage CRC had significantly more subclonal driver SCNAs 14 than early stage CRC, which suggested ITH of functional SCNAs rather than total absolute 15 SCNAs might be more closely related with CRC progress. 16
Germline mutations and ITH in CRC 17
Five patients in our study were found to have pathogenic or likely pathogenic germline 18 mutations in DNA mismatch repair genes. Among them, two (CRC05 and CRC15) patients 19 were hypermutated MSI patients identified with pathogenic and likely pathogenic mutations in 20 MLH1. In addition, CRC33 were found to carry a likely pathogenic mutation in the MLH1 gene, 21 CRC37 were presented with a pathogenic mutation in PMS2 gene and CRC44 were identified 22 with a pathogenic mutation in MLH3. CRC33 and CRC37 were left-sided colon cancer patient 23 and CRC44 was a rectal cancer patient. Interestingly, we found these 3 (CRC33, CRC37 and 24 CRC44) non-hypermutated MSS patients had relatively divergent and complex clonal evolution 25 with cluster number of 7, 6 and 8 respectively. These findings reminded us that germline 26 mutations in MSI genes might accelerate the evolution process in CRC. 27
Personalized therapy: Target-based Precision medicine for CRCPresently, the principle of treatment for CRC has shifted from 'one gene, one drug approach' 1 paradigm to a 'multi-gene, multi-drug' model when making decisions for precision medicine 63 . 2 It is of great clinical importance to define the mutation status, clonality of genes and biomarkers 3 in CRC. Among 62 CRC tumors, 32 were identified with driver mutations in KRAS while 7 4 were subclonal. Similarly, 7 CRC tumors harbored clonal driver mutations in PIK3CA, while 3 5 were carrying subclonal driver mutations. Driver mutations in NRAS (1 tumor), BRAF (4 tumors) 6 and ERBB2 (1 tumor) were all clonal in origin. In addition, among 4 driver mutations in BRAF, 7 2 were V600E. Furthermore, we identified 5 CRC tumors with EGFR amplification whilst only 8 1 was clonal in origin. No amplification of ERBB2 was found in our study. However, the 9 occurrence of subclonal driver mutations in biomarker genes emphasized the limitations of the 10 single biopsy strategy for the clinical diagnosis of CRC. In CRC59, we found all 4 tumor 11 regions had wildtype KRAS, BRAF and NRAS genes, whilst only 1 region had the driver 12 mutation in PIK3CA. CRC16  CRC02  CRC08  CRC03  CRC07  CRC10  CRC12  CRC14  CRC18  CRC11  CRC01  CRC06  CRC20  CRC22  CRC23  CRC27  CRC30  CRC31  CRC32  CRC35  CRC36  CRC37  CRC38  CRC24  CRC19  CRC21  CRC25  CRC26  CRC28  CRC34  CRC29 CRC44  CRC49  CRC50  CRC57  CRC58  CRC61  CRC65  CRC68  CRC39  CRC42  CRC47  CRC53  CRC56  CRC63  CRC66  CRC51  CRC43  CRC45  CRC46  CRC48  CRC52  CRC54  CRC55  CRC59  CRC60  CRC62  CRC64 CRC16  CRC49 CRC41 CRC57  CRC68 CRC40   CRC58  CRC50 CRC61  CRC65  CRC44   CRC20  CRC35 CRC37 CRC27 CRC32  CRC62 CRC42  CRC53 CRC56 CRC39   CRC36  CRC30  CRC31 CRC38 CRC24   CRC10 CRC03  CRC14 CRC07  CRC11  CRC34  CRC25 CRC19 CRC33  CRC29  CRC64  CRC52 CRC54  CRC45 CRC51   CRC66 CRC47   CRC23  CRC22   CRC08  CRC02   CRC18  CRC12  CRC46  CRC48  CRC60 CRC62  CRC59  CRC26 CRC21 CRC28   CRC55  CRC67 CRC43   CRC06  CRC01   cluster   1  2  3  4  5  6  7  8  9  10 Mutations and somatic copy-number alterations (SCNAs) is shown as occurrence in patients indicating whether the events are clonal (blue) or subclonal (red). Only genes that were mutated in at least five patients in total or two patients in right-sided colon/left-sided colon/ rectum are shown. For SCNAs, driver SCNAs in at least 20% of the patients are shown while all the arm level SCNAs are shown. Driver events with more subclonal occurrence than clonal occurrence in tumors were late events, otherwise they were early events. In the arm level SCNAs part, "G" represented gain, "L" represented loss, and the numbers in parentheses represented the time of occurrence in tumors. CRC42  CRC32  CRC49  CRC24  CRC60  CRC39  CRC38  CRC64  CRC57  CRC02  CRC52  CRC18  CRC61  CRC34  CRC16  CRC50  CRC63  CRC40  CRC43  CRC23  CRC03  CRC25  CRC11  CRC28  CRC07  CRC31  CRC45  CRC67  CRC53  CRC35  CRC54  CRC44  CRC06  CRC10  CRC48  CRC08  CRC12  CRC51  CRC21  CRC30  CRC46  CRC58  CRC14  CRC47  CRC56  CRC59  CRC62  CRC26  CRC36  CRC41  CRC27  CRC65  CRC19  CRC20  CRC33  CRC29  CRC66  CRC68  CRC22  CRC37 
